ChartRow logo
Data provided bySource: Twelve Data
BIO
$366.36-1.11%
as of close, Nov 13, 2026
☾ AH $366.36 -1.11%
PeersMDTTXGGMEDSNNWYPEN
Share this page

BIO — Bio-Rad Laboratories Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in BIO be worth today? →
BIO returns: By year · By month · By week · Trailing

Price data

Price
$366.36
YTD price return
+20.91%
YTD total return
+20.91%
Market cap
9.9B
Enterprise value
9.6B
Shares outstanding
26.9M
52W low
$236.73
52W high
$396.23
From 52W high
-7.54%
From 52W low
+54.76%
52W range
81%$237–$396

Volume

Rel volume
1.04×
30D volume
244.6K
30D $ vol
90.8M

Insider trading

Insider net 1W
−$1.2M
Insider net 1M
−$1.2M
Insider net 3M
−$1.2M
Insider net 1Y
−$1.4M

Form 4 transactions by trade date, as filed; latest on file 2026-11-10.

Fundamentals

Sales (ttm)
2.6B
Sales/share
$96.41
EPS (ttm)
$37.98
FCF (ttm)
329.1M
FCF/share
$12.24
Book value/share
$282.71
Net margin
39.45%
ROE
13.45%
ROA
9.49%
Debt / equity
0.11×
Current ratio
3.18

Growth (CAGR, ttm) · 10Y

Sales
+1.38%-1.59%-2.74%+2.29%
Net income
n/an/a-31.27%+45.76%
FCF
-2.29%+13.64%-13.17%+25.88%
Shares
-0.30%-2.64%-2.11%-0.98%

Per-share growth (CAGR, ttm) · 10Y

EPS
n/an/a-29.66%+28.13%
Sales/share
+1.69%+1.09%-0.65%+3.30%
FCF/share
-1.99%+16.72%-11.29%+27.12%
Book value/share
+13.21%-0.70%-11.22%+11.99%
Price
+15.62%+6.44%-13.49%+8.19%
Total return
+15.62%+6.44%-13.49%+8.19%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
9.6×
P/OI (ttm)
191.1×
Fwd P/E
37.2×
P/S (ttm)
3.8×
P/B (mrq)
1.3×
P/FCF (ttm)
29.9×
EV/Sales (ttm)
3.7×
FCF yield (ttm)
3.34%
Buyback yield (realized, 1y)
0.30%
Shareholder yield (realized, 1y)
0.30%
Buyback yield (cash, ttm)
0.80%
Shareholder yield (cash, ttm)
0.80%

Vs own 10Y history

P/E
45th
P/OI
98th
P/S
47th
P/B
29th
P/FCF
19th

Bar = where today’s multiple sits in BIO’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-13#

Data provided bySource: Twelve Data
1D
-1.11%
5D
-3.99%
1M
+0.72%
3M
+1.43%
YTD
+20.91%
1Y
+15.61%
5Y
-51.56%
1D
-1.11%
5D
-3.99%
1M
+0.72%
3M
+1.43%
YTD
+20.91%
1Y
+15.61%
5Y
-51.56%

Fundamentals#

Revenue

5Y CAGR +0.3%10Y CAGR +2.5%YoY +0.5%
$2.6B TTM$656.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR −35.5%10Y CAGR −11.9%YoY n/m
−$61.9M TTM−$49.7M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR −26.1%10Y CAGR +22.3%YoY n/m
$37.98 TTM$17.02 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR −4.7%10Y CAGR +17.6%YoY −26.9%
$329.1M TTM$65.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $468.1M, capex −$139M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $96.4M, capex −$31.2M

Shares (diluted)

5Y −9.5%10Y −7.2%YoY +0.1%
26.9M TTM26.9M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR −27.6%10Y CAGR +21.4%YoY n/m
$1B TTM$458.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full BIO financials →

About Bio-Rad Laboratories#

Data provided bySource: Twelve Data

Bio-Rad Laboratories Inc. is a life sciences and clinical diagnostics company that develops, manufactures, and markets products used in research laboratories, biopharmaceutical workflows, and healthcare testing. Bio-Rad Laboratories Inc. serves two main business segments: Life Science and Clinical Diagnostics. Its Life Science portfolio includes instruments, reagents, consumables, software, and content used to separate, purify, identify, and analyze biological materials such as cells, proteins, and nucleic acids. Its Clinical Diagnostics offerings include test systems, test kits, informatics tools, and quality controls used in areas such as diabetes monitoring, blood typing, infectious disease testing, autoimmune disorders, and genetic analysis. The company’s products are used by universities, hospitals, public health organizations, commercial laboratories, biotechnology firms, pharmaceutical companies, and food and environmental testing customers. Headquartered in Hercules, California, Bio-Rad Laboratories Inc. is recognized as a global supplier of tools that support scientific discovery and diagnostic decision-making.

Hercules, CA·7,450 employees·Medical Devices·bio-rad.com·As of Oct 30, 2026

Recent filings#

All filings and insider trades →

ETFs holding BIO#

19 of the 193 ETFs ChartRow carries live hold BIO. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IJHiShares Core S&P Mid-Cap ETF0.1%
MDYSPDR S&P MidCap 400 ETF Trust0.1%
VBRVanguard Small-Cap Value ETF0.1%
VHTVanguard Health Care ETF0.1%
VBVanguard Small-Cap ETF0.1%
VXFVanguard Extended Market ETF0.1%
IWSiShares Russell Mid-Cap Value ETF0.1%
IWRiShares Russell Midcap ETF0.0%
TickerName1M1D
LLYEli Lilly and Company+23.75%+1.14%
JNJJohnson & Johnson+14.94%+0.79%
ABBVAbbVie Inc.+7.53%+0.20%
UNHUnitedHealth Group Incorporated Common Stock (DE)+7.86%+0.58%
MRKMerck & Co. Inc.+4.07%+0.55%
NVSNovartis AG+12.70%+0.16%
TMOThermo Fisher Scientific Inc.+5.61%+0.11%
AMGNAmgen Inc.+12.80%-0.30%